Xin-Xin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xin-Xin Chen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Muli Wu
Department of Cardiovascular Disease Center First Affiliated Hospital of Shantou University Shantou University Shantou China
2 shared publications- Xiu-Hang Zhang
Department of Burns, The First Hospital of Jilin University, Changchun 130021, China
2 shared publications Yang Zheng
Department of Cardiovascular Disease Center First Hospital of Jilin University Jilin University Changchun China
2 shared publicationsChang-Lei Cui
Department of Anesthesiology, The First Hospital of Jilin University , Changchun , China
1 shared publication- Chang-Lei Cui
Department of Anesthesiology, The First Hospital of Jilin University, Chaoyang District, Xinmin Street, Street 71, Changchun City, Jilin Province 130021, China
1 shared publication - Chang-Lei Cui
Department of Burn Surgery, The First Hospital of Jilin University, Chaoyang District, Xinmin Street, Street 71, Changchun City, Jilin Province 130021, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Compuscript, Ltd. in Cardiovascular Innovations and Applications
- Vol. 9 (1) , 951
Current Outcomes after Revascularization for Coronary Very Late Stent Thrombosis
Objective: Limited data are available regarding current outcomes after revascularization for angiographically confirmed very late stent thrombosis (VLST). Therefore, this study investigated the current outcomes of patients with VLST and the risk factors for major adverse cardiovascular events (MACE). Methods: Consecutive patients who underwent revascularization for angiographically confirmed VLST between January 2014 and January 2016 were enrolled in this study. The patients were divided into two groups according to the occurrence of MACE during follow-up. The clinical and interventional parameters between groups were compared. Results: A total of 564 patients with an average age of 61.61 ± 10.71 years were enrolled. Eight patients died during hospitalization. MACE occurred in 100 patients after a mean follow-up of 620 days. The total MACE rate was 35.46%, and Kaplan-Meier survival analysis indicated an estimated MACE-free survival rate of 22%. Multivariable Cox regression analysis revealed that left ventricular ejection fraction and peak troponin I at VLST onset were independent predictors of MACE. Conclusions: Long-term outcomes after revascularization for VLST remained unfavorable. Left ventricular ejection fraction and peak troponin I at the onset of VLST were independent risk factors for poor prognosis.
- 1 January 2024
- Published by Compuscript, Ltd. in Cardiovascular Innovations and Applications
- Vol. 9 (1) , 951
Open AccessCurrent Outcomes after Revascularization for Coronary Very Late Stent Thrombosis
Objective: Limited data are available regarding current outcomes after revascularization for angiographically confirmed very late stent thrombosis (VLST). Therefore, this study investigated the current outcomes of patients with VLST and the risk factors for major adverse cardiovascular events (MACE). Methods: Consecutive patients who underwent revascularization for angiographically confirmed VLST between January 2014 and January 2016 were enrolled in this study. The patients were divided into two groups according to the occurrence of MACE during follow-up. The clinical and interventional parameters between groups were compared. Results: A total of 564 patients with an average age of 61.61 ± 10.71 years were enrolled. Eight patients died during hospitalization. MACE occurred in 100 patients after a mean follow-up of 620 days. The total MACE rate was 35.46%, and Kaplan-Meier survival analysis indicated an estimated MACE-free survival rate of 22%. Multivariable Cox regression analysis revealed that left ventricular ejection fraction and peak troponin I at VLST onset were independent predictors of MACE. Conclusions: Long-term outcomes after revascularization for VLST remained unfavorable. Left ventricular ejection fraction and peak troponin I at the onset of VLST were independent risk factors for poor prognosis.
- 1 February 2020
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 44 (3) , 715-722
The Effects of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor Gel on Third-Degree Frostbite Wounds in Northeastern China: A Randomized Controlled Trial
The aim of the study was to investigate the effects of the rhGM-CSF gel on third degree frostbite wounds. 62 patients who had suffered third degree frostbite on their hand or foot (91 wounds in total ) were selected using a convenience sampling method and randomly allocated to two groups: the rhGM-CSF group(31patients,45 frostbite wounds) received the rhGM-CSF gel when wound dressing change daily, however, the control group (31patients, 46 frostbite wounds) received aloe glue. The wound healing time , the score of inflammation about the wound and the positive bacterial culture of wound secretions was used to measure outcomes respectively. Data were analyzed using SPSS (25.0), student's t test or Mann-Whitney U test and Chi-square test or Fisher exact test were selected, as appropriate. The healing time of the rhGM-CSF group was (12.2±5.0) days, which was significantly shorter than that of the control group (15.5±4.7) days (P th and 14th day of treatment were (0.96±0.21) and (1.88±0.29) respectively, which were better than those of the control group (1.12±0.24) and (1.38±0.15) (both P rd , 7th and 14th day after treatment (P =0.027, 0.004, 0.030 respectively). According to the results, using rhGM-CSF gel considerably increases the speed of frostbite wounds healing, and have an effect on protecting third degree frostbite wounds regarding the positive effects.
- 1 February 2020
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 44 (3) , 715-722
The Effects of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor Gel on Third-Degree Frostbite Wounds in Northeastern China: A Randomized Controlled Trial
The aim of the study was to investigate the effects of the rhGM-CSF gel on third degree frostbite wounds. 62 patients who had suffered third degree frostbite on their hand or foot (91 wounds in total ) were selected using a convenience sampling method and randomly allocated to two groups: the rhGM-CSF group(31patients,45 frostbite wounds) received the rhGM-CSF gel when wound dressing change daily, however, the control group (31patients, 46 frostbite wounds) received aloe glue. The wound healing time , the score of inflammation about the wound and the positive bacterial culture of wound secretions was used to measure outcomes respectively. Data were analyzed using SPSS (25.0), student's t test or Mann-Whitney U test and Chi-square test or Fisher exact test were selected, as appropriate. The healing time of the rhGM-CSF group was (12.2±5.0) days, which was significantly shorter than that of the control group (15.5±4.7) days (P th and 14th day of treatment were (0.96±0.21) and (1.88±0.29) respectively, which were better than those of the control group (1.12±0.24) and (1.38±0.15) (both P rd , 7th and 14th day after treatment (P =0.027, 0.004, 0.030 respectively). According to the results, using rhGM-CSF gel considerably increases the speed of frostbite wounds healing, and have an effect on protecting third degree frostbite wounds regarding the positive effects.
- Open Access
- 1 January 2020
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 26
The Association Between S100A8/A9 and the Development of Very Late Stent Thrombosis in Patients With Acute Myocardial Infarction
Very late stent thrombosis (VLST) is a rare but serious complication following percutaneous coronary intervention (PCI). S100A8/A9 plays an important role in thrombosis through modulating the inflammatory response. This observational study aimed to reveal the association between S100A8/A9 and VLST. Continuous blood samples were collected from patients at both the time of index PCI for acute myocardial infarction (AMI) and the time of PCI for VLST (VLST group) or follow-up coronary angiography (AMI group). In all, 56 patients were selected in each group from a cohort of 8476 patients and other 112 individuals who underwent health checkups (normal control [NC] group) were selected as controls. Serum levels of S100A8/A9 and high sensitivity C-reactive protein (hs-CRP) were tested and compared. The mean level of S100A8/A9 was 3754.4 ± 1688.9 ng/mL during index PCI and increased to 5517.8 ± 2650.9 ng/mL at the time of VLST; in the AMI group, S100A8/A9 level was 2434.9 ± 1243.4 ng/mL during index PCI and decreased to 1568.2 ± 772.1 ng/mL during follow-up, similar to that detected in the NC group (1618.2 ± 641.4 ng/mL). Of note, S100A8/A9 levels showed significant increases during VLST when compared to its own levels during index PCI, which was different from the changes of hs-CRP. Higher serum levels of S100A8/A9 are associated with the development of VLST.
- 1 January 2020
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 26
Open AccessThe Association Between S100A8/A9 and the Development of Very Late Stent Thrombosis in Patients With Acute Myocardial Infarction
Very late stent thrombosis (VLST) is a rare but serious complication following percutaneous coronary intervention (PCI). S100A8/A9 plays an important role in thrombosis through modulating the inflammatory response. This observational study aimed to reveal the association between S100A8/A9 and VLST. Continuous blood samples were collected from patients at both the time of index PCI for acute myocardial infarction (AMI) and the time of PCI for VLST (VLST group) or follow-up coronary angiography (AMI group). In all, 56 patients were selected in each group from a cohort of 8476 patients and other 112 individuals who underwent health checkups (normal control [NC] group) were selected as controls. Serum levels of S100A8/A9 and high sensitivity C-reactive protein (hs-CRP) were tested and compared. The mean level of S100A8/A9 was 3754.4 ± 1688.9 ng/mL during index PCI and increased to 5517.8 ± 2650.9 ng/mL at the time of VLST; in the AMI group, S100A8/A9 level was 2434.9 ± 1243.4 ng/mL during index PCI and decreased to 1568.2 ± 772.1 ng/mL during follow-up, similar to that detected in the NC group (1618.2 ± 641.4 ng/mL). Of note, S100A8/A9 levels showed significant increases during VLST when compared to its own levels during index PCI, which was different from the changes of hs-CRP. Higher serum levels of S100A8/A9 are associated with the development of VLST.